Metrovacesa S.A.

BME:MVC Stock Report

Market Cap: €1.8b

Metrovacesa Past Earnings Performance

Past criteria checks 4/6

Metrovacesa has been growing earnings at an average annual rate of 54.1%, while the Real Estate industry saw earnings growing at 18% annually. Revenues have been growing at an average rate of 16.4% per year. Metrovacesa's return on equity is 4%, and it has net margins of 8%.

Key information

54.14%

Earnings growth rate

61.06%

EPS growth rate

Real Estate Industry Growth17.43%
Revenue growth rate16.39%
Return on equity4.02%
Net Margin8.03%
Next Earnings Update22 Jul 2026

Recent past performance updates

Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Recent updates

MVC: Higher Required Return And Rich P/E Will Pressure Future Returns

Analysts have kept their price target for Metrovacesa broadly unchanged at around €10.81 per share. The latest revisions reflect only very small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.

MVC: Stable Assumptions And Discount Rate Tweaks Will Guide Future Returns

Analysts keep their Metrovacesa price target steady at €10.81, indicating largely unchanged assumptions on fair value, growth, margins, and future P/E, with only minor adjustments to discount rates and long-term expectations. Valuation Changes Fair Value: €10.81 per share is unchanged, suggesting the core view of what the stock is worth on a fundamental basis remains the same.

MVC: Dividend Outlook And Revised Assumptions Will Shape Future Return Balance

Analysts now set their fair value estimate for Metrovacesa at €10.81 per share, up from €10.63. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.

MVC: Lower Growth Assumptions And Elevated P/E Will Sustain Bearish View

Analysts have modestly lowered their price target on Metrovacesa to €9.30, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, while keeping their fair value estimate unchanged at €9.30. Valuation Changes Fair Value: The fair value estimate is unchanged at €9.30 per share, indicating no revision to the overall valuation outcome.

MVC: Dividend Outlook And Updated Assumptions Will Shape Future Return Balance

Analysts have slightly trimmed their fair value estimate for Metrovacesa from €10.83 to €10.63, citing updated assumptions around discount rates, expected revenue growth, margins and future P/E levels. Valuation Changes Fair Value: Trimmed slightly from €10.83 to €10.63 per share.

MVC: Lower Discount Rate And High P/E Will Sustain Bearish View

Analysts have slightly raised their price target on Metrovacesa, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together indicate a modestly higher fair value per share in euro terms. Valuation Changes Fair Value: unchanged at €9.30 per share.

MVC: Dividend Reserve Plans And P/E Revisions Will Guide Cautious Outlook

Analysts have maintained their Metrovacesa fair value target at €9.30, citing a combination of updated assumptions that include slightly lower discount rates, higher revenue growth expectations, softer profit margins and a higher future P/E multiple in their latest models. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments).

MVC: Dividend Proposal At Extraordinary Meeting Will Support Bullish Thesis

Analysts have revised their price target on Metrovacesa from €11.80 to €13.10, citing updated assumptions around discount rates, revenue growth, profit margins, and the future P/E multiple. What's in the News Metrovacesa has scheduled a Special and Extraordinary Shareholders Meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (calle principe de vergara 187, plaza de rodrigo uria, madrid) (Key Developments) The meeting agenda includes a proposal to discuss the distribution of dividends from freely distributable reserves, which may be relevant if you are focusing on potential cash returns to shareholders (Key Developments) The notice also refers to discussion of other matters at the meeting, indicating that additional shareholder topics could be addressed beyond dividends (Key Developments) Valuation Changes Fair Value Estimate was revised from €11.80 to €13.10, indicating a higher assessed value per share.

MVC: Dividend Reserve Plans Will Shape A Cautious Medium-Term Outlook

Analysts have raised their price target on Metrovacesa from €6.50 to €9.30, citing higher expected revenue growth, improved profit margins, and a modestly richer future P/E multiple, despite a slightly higher discount rate. What's in the News Metrovacesa has called a special shareholders meeting for November 25, 2025, at 13:00 CET in Madrid to address key corporate matters.

Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate

Dec 20
Metrovacesa S.A. (BME:MVC) Shares Could Be 23% Below Their Intrinsic Value Estimate

MVC: Dividend Decision And Revised Outlook Will Shape Balanced Return Prospects

Analysts have raised their price target on Metrovacesa from €9.81 to €10.83, citing a higher long term fair value despite moderating assumptions for revenue growth, profit margins and future earnings multiples. What's in the News Metrovacesa has scheduled a special and extraordinary shareholders meeting for November 25, 2025, at 13:00 Central European Standard Time in Madrid, Spain (Key Developments) The main agenda item for the upcoming meeting is the potential distribution of dividends from freely distributable reserves, which could affect shareholder returns policy (Key Developments) Shareholders will also address other unspecified matters at the meeting, leaving scope for additional corporate or capital structure decisions (Key Developments) Valuation Changes Fair Value: raised slightly from €9.81 to €10.83 per share, reflecting a modest uplift in long term valuation.

Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?

Oct 02
Should You Think About Buying Metrovacesa S.A. (BME:MVC) Now?

Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Jul 25
Calculating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

May 04
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?

Apr 12
Are Investors Undervaluing Metrovacesa S.A. (BME:MVC) By 40%?

Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest

Feb 26
Metrovacesa's (BME:MVC) Performance Is Even Better Than Its Earnings Suggest
User avatar

Will Leverage Undersupplied Spanish Housing Market For Future Opportunities

High presales coverage allows focus on margin maximization, boosting future net margins amid an undersupplied market.

Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?

Feb 07
Is It Time To Consider Buying Metrovacesa S.A. (BME:MVC)?

An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued

Dec 13
An Intrinsic Calculation For Metrovacesa S.A. (BME:MVC) Suggests It's 44% Undervalued

Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

Sep 12
Estimating The Fair Value Of Metrovacesa S.A. (BME:MVC)

We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Aug 01
We Think Metrovacesa's (BME:MVC) Profit Is Only A Baseline For What They Can Achieve

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Jul 17
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

May 28
A Look At The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

May 01
We Think Metrovacesa (BME:MVC) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Mar 27
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Feb 12
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Nov 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

Jul 05
These 4 Measures Indicate That Metrovacesa (BME:MVC) Is Using Debt Extensively

Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

May 21
Is Now An Opportune Moment To Examine Metrovacesa S.A. (BME:MVC)?

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Apr 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Dec 02
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

Sep 23
Is It Too Late To Consider Buying Metrovacesa S.A. (BME:MVC)?

Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

May 19
Estimating The Intrinsic Value Of Metrovacesa S.A. (BME:MVC)

Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Mar 05
Metrovacesa's (BME:MVC) Strong Earnings Are Of Good Quality

Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Feb 16
Would Metrovacesa (BME:MVC) Be Better Off With Less Debt?

Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Oct 05
Does Metrovacesa (BME:MVC) Have A Healthy Balance Sheet?

Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Jul 02
Is Metrovacesa S.A. (BME:MVC) Worth €6.7 Based On Its Intrinsic Value?

Is Metrovacesa (BME:MVC) Using Too Much Debt?

May 06
Is Metrovacesa (BME:MVC) Using Too Much Debt?

Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Apr 06
Is Metrovacesa S.A. (BME:MVC) A Strong Dividend Stock?

Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Mar 15
Metrovacesa (BME:MVC) Share Prices Have Dropped 51% In The Last Three Years

Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

Feb 16
Loss-Making Metrovacesa S.A. (BME:MVC) Set To Breakeven

When Should You Buy Metrovacesa S.A. (BME:MVC)?

Jan 26
When Should You Buy Metrovacesa S.A. (BME:MVC)?

A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

Jan 05
A Look At The Fair Value Of Metrovacesa S.A. (BME:MVC)

If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Dec 14
If You Had Bought Metrovacesa's (BME:MVC) Shares A Year Ago You Would Be Down 24%

Revenue & Expenses Breakdown

How Metrovacesa makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BME:MVC Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2570857510
30 Sep 2563227510
30 Jun 25555-3510
31 Mar 256046520
31 Dec 2465316540
30 Sep 2465117530
30 Jun 2464918530
31 Mar 24616-15530
31 Dec 23581-21520
30 Sep 23535-68510
30 Jun 23430-71520
31 Mar 23454-38510
31 Dec 22516-23510
30 Sep 2252925570
30 Jun 2257233560
31 Mar 2257531550
31 Dec 2151218530
30 Sep 21413-71470
30 Jun 21231-90400
31 Mar 21138-160340
31 Dec 20140-164340
30 Sep 20164-87340
30 Jun 20180-87340
31 Mar 20214-6350
31 Dec 19161-4340
30 Sep 192060330
30 Jun 192205310
31 Mar 19211-11280
31 Dec 18190-9290
30 Sep 18103-14230
30 Jun 1870-31260
31 Mar 1834-34180
31 Dec 1728-39150
30 Sep 1729-55110
31 Dec 1621-2170
31 Dec 15366480

Quality Earnings: MVC has a large one-off loss of €36.9M impacting its last 12 months of financial results to 31st December, 2025.

Growing Profit Margin: MVC's current net profit margins (8%) are higher than last year (2.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MVC has become profitable over the past 5 years, growing earnings by 54.1% per year.

Accelerating Growth: MVC's earnings growth over the past year (257.9%) exceeds its 5-year average (54.1% per year).

Earnings vs Industry: MVC earnings growth over the past year (257.9%) exceeded the Real Estate industry 41.7%.

Return on Equity

High ROE: MVC's Return on Equity (4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/29 10:44
End of Day Share Price 2026/04/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Metrovacesa S.A. is covered by 22 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ignacio RomeroBanco de Sabadell. S.A.
null nullBanco de Sabadell. S.A.
Mariano Miguel HidalgoBanco Santander